Menu Search
Equities

Bicycle Therapeutics PLC

50BA:FRA

Bicycle Therapeutics PLC

Actions
  • Price (EUR)22.40
  • Today's Change0.20 / 0.90%
  • Shares traded400.00
  • 1 Year change+16.06%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Bicycle Therapeutics PLC had net income fall 60.28% from a loss of 112.72m to a larger loss of 180.66m despite a 86.52% increase in revenues from 14.46m to 26.98m.
Gross margin--
Net profit margin-417.88%
Operating margin-463.42%
Return on assets-21.88%
Return on equity-30.24%
Return on investment-24.15%
More ▼

Cash flow in USDView more

In 2023, Bicycle Therapeutics PLC increased its cash reserves by 55.38%, or 187.82m. Cash Flow from Financing totalled 250.03m or 926.85% of revenues. In addition the company used 60.63m for operations while cash used for investing totalled 2.93m.
Cash flow per share-3.59
Price/Cash flow per share--
Book value per share12.67
Tangible book value per share12.67
More ▼

Balance sheet in USDView more

Bicycle Therapeutics PLC has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 526.42m.
Current ratio14.77
Quick ratio--
Total debt/total equity0.0354
Total debt/total capital0.0342
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.